EUCTR2005-003119-62-DE进行中（未招募）不适用
Double-blind, double-dummy, randomized, parallel group trial of SL650472 (three dose regimens versus placebo and cilostazol), for 24-week improvement of walking distance in patients with stage II peripheral arterial disease who benefit from optimal prevention strategy including clopidogrel. - MASCOT
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 580
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria at screening visit:
- •Diagnosis of intermittent claudication
- •1. Patient with stable symptoms of intermittent claudication of the lower extremities, secondary to chronic occlusive arterial disease from atherosclerosis origin (symptoms present for 6 months or longer and not significantly changed within the past 3 months);
- •2. ICD of 30 to 200 m at screening constant workload treadmill test.
- •Confirmation of underlying PAD
- •3. Doppler-measured pre-treadmill ABI of 0.90 or lower after 10 minutes of rest or, for patients with an ABI of greater than 1.3 (non-compressible arteries), a Toe-Brachial Index (TBI) of less than 0.7.
- •Appropriate background therapy
- •4. Patient following a supervised or unsupervised program of exercise training and smoking cessation (if smoker) for at least 3 months prior to screening, and accepting to continue it for the entire study duration;
- •5. Patient who can be treated by clopidogrel 75 mg OD from screening visit to 24-week visit.
- •Inclusion criteria at randomization:
- •Confirmation of symptoms stability
- •6. Mean ICD of 30 to 200 m calculated by averaging the constant workload treadmill test performed at the end of the run-in phase and the previous one performed 14 to 17 days before;
- •7. Percent change less than or equal to 25 % between those two ICD measurements, as per international recommendation.
- •Compliance to investigational products administration
- •8. At least 80 % of clopidogrel and 80 % of placebo tablets/capsules taken during the run-in phase.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria at screening/randomization visits
- •1. Patient not having provided written informed consent.
- •2. Patient previously screened for or included in this study.
- •Potentially non-atherosclerotic and/or severe stage disease not amenable to medical therapy
- •3. Age below 40 years and/or onset of symptoms of PAD before the age of 40 years;
- •4. Non-atherosclerotic vascular disease (e.g. Buerger’s disease, popliteal entrapment syndrome);
- •5. Limb-threatening (grades III and IV) chronic limb ischemia, manifested by ischemic rest pain, ulceration, or gangrene.
- •Current (or within the 3 months prior to screening) pharmacological treatment likely to interfere with study endpoints
- •6. Recent initiation or discontinuation of treatment by vasoactive agents (including cilostazol, naftidrofuryl, pentoxyfilline, beraprost sodium, papaverine, isoxsuprine, nylidrin, cyclandelate, and niacin derivatives), or high-dose atorvastatin (80 mg OD) or warfarin/coumadin.
- •Recent (within 3 months prior to screening or during the run-in phase) changes in local and/or general conditions likely to interfere with study endpoints
- •7. Recent lower-extremity surgical or endovascular arterial reconstructions or sympathectomy, or recent deep venous thrombosis;
- •8. Recent change in the level of compliance to supervised or unsupervised program of exercise training and smoking cessation (whatever the grade of compliance, it should remain the same during this period);
- •9. Recent occurrence of at least one of the following: acute myocardial infarction (MI), unstable angina (UA), coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) transient ischemic attack (TIA) or stroke;
- •Presence of medical and/or social problems (at screening or during the run-in phase) that would either interfere with participation in the trial, or lead to inability to complete the trial
- •10. Conditions other than claudication likely to jeopardize completion and/or safety of the treadmill testing, including angina, electrocardiographic or clinical evidence of significant myocardial ischemia (ischemic ST-segment depression greater than 0.2 mV in any lead) or QT prolongation (QTc = 500 ms), dyspnea, fatigue, orthopedic, or rheumatologic symptoms, severe obesity (BMI =35), uncontrolled hypertension (blood pressure greater than 200/100 mm Hg) or significant hypotension (systolic blood pressure less than 90 mm Hg), severe valvular disease, restrictive or hypertrophic cardiomyopathy
- •11. Planned cardiac or vascular surgery or angioplasty or any major surgery within the next 6 months;
- •12. Severe concomitant disease such that the patient is not expected to survive 6 months;
- •13. Receipt of any investigational treatment (drug or device) within the previous 30 days;
- •14. Previous disabling condition with a severe cerebral deficit, such that the patient is bedridden or demented;
- •15. Geographic or social factors making study participation impractical;
- •16. Unable to understand the full meaning of the informed consent.
- •Contra-indications to the use of cilostazol, or conditions likely to dramatically affect pharmacokinetics of cilostazol and/or SL650472
- •17. History of congestive heart failure of any severity;
- •18. History of drug allergy to cilostazol;
- •19. Pregnant or breast-feeding women, or women planning to become pregnant or breast-feed;
- •20. Severe hepatic insufficiency;
- •21. Severe renal failure (serum creatinine greater than 2.5 mg/dL [220 µmol/L] and / or clearance less than 30 mL/min a
研究者
相似试验
进行中（未招募）
不适用
Double-blind, double-dummy, randomized, parallel group trial of SL650472 (three dose regimens versus placebo and cilostazol), for 24-week improvement of walking distance in patients with stage II peripheral arterial disease who benefit from optimal prevention strategy including clopidogrel. - MASCOTEUCTR2005-003119-62-CZsanofi-aventis recherche & développement580
进行中（未招募）
不适用
Double-blind, double-dummy, randomized, parallel group trial of SL650472 (three dose regimens versus placebo and cilostazol), for 24-week improvement of walking distance in patients with stage II peripheral arterial disease who benefit from optimal prevention strategy including clopidogrel. - MASCOTPeripheral arterial disease (intermittent claudication) Fontaine stage IIMedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2005-003119-62-SEsanofi-aventis recherche & développement580
进行中（未招募）
1 期
Double-blind, double-dummy, randomized, parallel group trial of SL650472 (three dose regimens versus placebo and cilostazol), for 24-week improvement of walking distance in patients with stage II peripheral arterial disease who benefit from optimal prevention strategy including clopidogrel. - MASCOTPeripheral arterial disease (intermittent claudication) Fontaine stage IIMedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2005-003119-62-BEsanofi-aventis recherche & développement580
进行中（未招募）
1 期
Randomized, double-blind, double-dummy, parallel group, multicenter study to compare the efficacy and safety of once-monthly oral administration of 150 mg ibandronate with once-weekly oral administration of 70 mg alendronate in postmenopausal osteoporosis - Non-inferiority trialEUCTR2004-002255-14-DKF. Hoffmann-La Roche Ltd1,786
进行中（未招募）
不适用
Randomized, double-blind, double-dummy, parallel group, multicenter study to compare the efficacy and safety of once-monthly oral administration of 150 mg ibandronate with once-weekly oral administration of 70 mg alendronate in postmenopausal osteoporosis - Non-inferiority trialStudy in women with postmenopausal osteoporosis.EUCTR2004-002255-14-HUF. Hoffmann-La Roche Ltd1,786